> top > docs > PubMed:18199556 > annotations

PubMed:18199556 JSONTXT

Annnotations TAB JSON ListView MergeView

PMID_GLOBAL

Id Subject Object Predicate Lexical cue mondo_id
T1 259-270 DiseaseOrPhenotypicFeature denotes lung cancer 0005138|0008903
T3 655-664 DiseaseOrPhenotypicFeature denotes sensitive 0000605
T4 749-768 DiseaseOrPhenotypicFeature denotes lung adenocarcinoma 0005061

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-141 Sentence denotes Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
TextSentencer_T2 142-340 Sentence denotes Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) are found in a subset of patients with lung cancer and correlate with response to EGFR tyrosine kinase inhibitors (TKI).
TextSentencer_T3 341-460 Sentence denotes Resistance to these agents invariably develops, and current treatment strategies have limited efficacy in this setting.
TextSentencer_T4 461-679 Sentence denotes Hsp90 inhibitors, such as 17-allylamino-17-demethoxygeldanamycin (17-AAG), induce the degradation of EGFR and other Hsp90 interacting proteins and may thus have utility in tumors dependent upon sensitive Hsp90 clients.
TextSentencer_T5 680-826 Sentence denotes We find that the EGFR mutations found most commonly in patients with lung adenocarcinoma who respond to EGFR TKIs are potently degraded by 17-AAG.
TextSentencer_T6 827-998 Sentence denotes Although the expression of wild-type EGFR was also down-regulated by 17-AAG, its degradation required higher concentrations of drug and a longer duration of drug exposure.
TextSentencer_T7 999-1126 Sentence denotes In animal models, a single dose of 17-AAG was sufficient to induce degradation of mutant EGFR and inhibit downstream signaling.
TextSentencer_T8 1127-1293 Sentence denotes 17-AAG treatment, at its maximal tolerated dose, caused a significant delay in H3255 (L858R EGFR) xenograft growth but was less effective than the EGFR TKI gefitinib.
TextSentencer_T9 1294-1477 Sentence denotes 17-AAG alone delayed, but did not completely inhibit, the growth of H1650 and H1975 xenografts, two EGFR mutant models which show intermediate and high levels of gefitinib resistance.
TextSentencer_T10 1478-1609 Sentence denotes 17-AAG could be safely coadministered with paclitaxel, and the combination was significantly more effective than either drug alone.
TextSentencer_T11 1610-1860 Sentence denotes These data suggest that Hsp90 inhibition in combination with chemotherapy may represent an effective treatment strategy for patients whose tumors express EGFR kinase domain mutations, including those with de novo and acquired resistance to EGFR TKIs.
T1 0-141 Sentence denotes Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
T2 142-340 Sentence denotes Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) are found in a subset of patients with lung cancer and correlate with response to EGFR tyrosine kinase inhibitors (TKI).
T3 341-460 Sentence denotes Resistance to these agents invariably develops, and current treatment strategies have limited efficacy in this setting.
T4 461-679 Sentence denotes Hsp90 inhibitors, such as 17-allylamino-17-demethoxygeldanamycin (17-AAG), induce the degradation of EGFR and other Hsp90 interacting proteins and may thus have utility in tumors dependent upon sensitive Hsp90 clients.
T5 680-826 Sentence denotes We find that the EGFR mutations found most commonly in patients with lung adenocarcinoma who respond to EGFR TKIs are potently degraded by 17-AAG.
T6 827-998 Sentence denotes Although the expression of wild-type EGFR was also down-regulated by 17-AAG, its degradation required higher concentrations of drug and a longer duration of drug exposure.
T7 999-1126 Sentence denotes In animal models, a single dose of 17-AAG was sufficient to induce degradation of mutant EGFR and inhibit downstream signaling.
T8 1127-1293 Sentence denotes 17-AAG treatment, at its maximal tolerated dose, caused a significant delay in H3255 (L858R EGFR) xenograft growth but was less effective than the EGFR TKI gefitinib.
T9 1294-1477 Sentence denotes 17-AAG alone delayed, but did not completely inhibit, the growth of H1650 and H1975 xenografts, two EGFR mutant models which show intermediate and high levels of gefitinib resistance.
T10 1478-1609 Sentence denotes 17-AAG could be safely coadministered with paclitaxel, and the combination was significantly more effective than either drug alone.
T11 1610-1860 Sentence denotes These data suggest that Hsp90 inhibition in combination with chemotherapy may represent an effective treatment strategy for patients whose tumors express EGFR kinase domain mutations, including those with de novo and acquired resistance to EGFR TKIs.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 180-212 gene:1956 denotes epidermal growth factor receptor
T1 259-270 disease:C0242379 denotes lung cancer
T2 180-212 gene:1956 denotes epidermal growth factor receptor
T3 259-270 disease:C0684249 denotes lung cancer
T4 214-218 gene:1956 denotes EGFR
T5 259-270 disease:C0242379 denotes lung cancer
T6 214-218 gene:1956 denotes EGFR
T7 259-270 disease:C0684249 denotes lung cancer
T8 302-306 gene:1956 denotes EGFR
T9 259-270 disease:C0684249 denotes lung cancer
T10 302-306 gene:1956 denotes EGFR
T11 259-270 disease:C0242379 denotes lung cancer
T12 697-701 gene:1956 denotes EGFR
T13 749-768 disease:C0152013 denotes lung adenocarcinoma
T14 784-788 gene:1956 denotes EGFR
T15 749-768 disease:C0152013 denotes lung adenocarcinoma
R1 T0 T1 associated_with epidermal growth factor receptor,lung cancer
R2 T2 T3 associated_with epidermal growth factor receptor,lung cancer
R3 T4 T5 associated_with EGFR,lung cancer
R4 T6 T7 associated_with EGFR,lung cancer
R5 T8 T9 associated_with EGFR,lung cancer
R6 T10 T11 associated_with EGFR,lung cancer
R7 T12 T13 associated_with EGFR,lung adenocarcinoma
R8 T14 T15 associated_with EGFR,lung adenocarcinoma

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
18199556-1#38#70#gene1956 180-212 gene1956 denotes epidermal growth factor receptor
18199556-1#72#76#gene1956 214-218 gene1956 denotes EGFR
18199556-1#160#164#gene1956 302-306 gene1956 denotes EGFR
18199556-1#117#128#diseaseC0242379 259-270 diseaseC0242379 denotes lung cancer
18199556-1#117#128#diseaseC0684249 259-270 diseaseC0684249 denotes lung cancer
18199556-1#117#128#diseaseC1306460 259-270 diseaseC1306460 denotes lung cancer
18199556-1#117#128#diseaseC0242379 259-270 diseaseC0242379 denotes lung cancer
18199556-1#117#128#diseaseC0684249 259-270 diseaseC0684249 denotes lung cancer
18199556-1#117#128#diseaseC1306460 259-270 diseaseC1306460 denotes lung cancer
18199556-1#117#128#diseaseC0242379 259-270 diseaseC0242379 denotes lung cancer
18199556-1#117#128#diseaseC0684249 259-270 diseaseC0684249 denotes lung cancer
18199556-1#117#128#diseaseC1306460 259-270 diseaseC1306460 denotes lung cancer
18199556-4#17#21#gene1956 697-701 gene1956 denotes EGFR
18199556-4#104#108#gene1956 784-788 gene1956 denotes EGFR
18199556-4#69#88#diseaseC0152013 749-768 diseaseC0152013 denotes lung adenocarcinoma
38#70#gene1956117#128#diseaseC0242379 18199556-1#38#70#gene1956 18199556-1#117#128#diseaseC0242379 associated_with epidermal growth factor receptor,lung cancer
38#70#gene1956117#128#diseaseC0684249 18199556-1#38#70#gene1956 18199556-1#117#128#diseaseC0684249 associated_with epidermal growth factor receptor,lung cancer
38#70#gene1956117#128#diseaseC1306460 18199556-1#38#70#gene1956 18199556-1#117#128#diseaseC1306460 associated_with epidermal growth factor receptor,lung cancer
38#70#gene1956117#128#diseaseC0242379 18199556-1#38#70#gene1956 18199556-1#117#128#diseaseC0242379 associated_with epidermal growth factor receptor,lung cancer
38#70#gene1956117#128#diseaseC0684249 18199556-1#38#70#gene1956 18199556-1#117#128#diseaseC0684249 associated_with epidermal growth factor receptor,lung cancer
38#70#gene1956117#128#diseaseC1306460 18199556-1#38#70#gene1956 18199556-1#117#128#diseaseC1306460 associated_with epidermal growth factor receptor,lung cancer
38#70#gene1956117#128#diseaseC0242379 18199556-1#38#70#gene1956 18199556-1#117#128#diseaseC0242379 associated_with epidermal growth factor receptor,lung cancer
38#70#gene1956117#128#diseaseC0684249 18199556-1#38#70#gene1956 18199556-1#117#128#diseaseC0684249 associated_with epidermal growth factor receptor,lung cancer
38#70#gene1956117#128#diseaseC1306460 18199556-1#38#70#gene1956 18199556-1#117#128#diseaseC1306460 associated_with epidermal growth factor receptor,lung cancer
72#76#gene1956117#128#diseaseC0242379 18199556-1#72#76#gene1956 18199556-1#117#128#diseaseC0242379 associated_with EGFR,lung cancer
72#76#gene1956117#128#diseaseC0684249 18199556-1#72#76#gene1956 18199556-1#117#128#diseaseC0684249 associated_with EGFR,lung cancer
72#76#gene1956117#128#diseaseC1306460 18199556-1#72#76#gene1956 18199556-1#117#128#diseaseC1306460 associated_with EGFR,lung cancer
72#76#gene1956117#128#diseaseC0242379 18199556-1#72#76#gene1956 18199556-1#117#128#diseaseC0242379 associated_with EGFR,lung cancer
72#76#gene1956117#128#diseaseC0684249 18199556-1#72#76#gene1956 18199556-1#117#128#diseaseC0684249 associated_with EGFR,lung cancer
72#76#gene1956117#128#diseaseC1306460 18199556-1#72#76#gene1956 18199556-1#117#128#diseaseC1306460 associated_with EGFR,lung cancer
72#76#gene1956117#128#diseaseC0242379 18199556-1#72#76#gene1956 18199556-1#117#128#diseaseC0242379 associated_with EGFR,lung cancer
72#76#gene1956117#128#diseaseC0684249 18199556-1#72#76#gene1956 18199556-1#117#128#diseaseC0684249 associated_with EGFR,lung cancer
72#76#gene1956117#128#diseaseC1306460 18199556-1#72#76#gene1956 18199556-1#117#128#diseaseC1306460 associated_with EGFR,lung cancer
160#164#gene1956117#128#diseaseC0242379 18199556-1#160#164#gene1956 18199556-1#117#128#diseaseC0242379 associated_with EGFR,lung cancer
160#164#gene1956117#128#diseaseC0684249 18199556-1#160#164#gene1956 18199556-1#117#128#diseaseC0684249 associated_with EGFR,lung cancer
160#164#gene1956117#128#diseaseC1306460 18199556-1#160#164#gene1956 18199556-1#117#128#diseaseC1306460 associated_with EGFR,lung cancer
160#164#gene1956117#128#diseaseC0242379 18199556-1#160#164#gene1956 18199556-1#117#128#diseaseC0242379 associated_with EGFR,lung cancer
160#164#gene1956117#128#diseaseC0684249 18199556-1#160#164#gene1956 18199556-1#117#128#diseaseC0684249 associated_with EGFR,lung cancer
160#164#gene1956117#128#diseaseC1306460 18199556-1#160#164#gene1956 18199556-1#117#128#diseaseC1306460 associated_with EGFR,lung cancer
160#164#gene1956117#128#diseaseC0242379 18199556-1#160#164#gene1956 18199556-1#117#128#diseaseC0242379 associated_with EGFR,lung cancer
160#164#gene1956117#128#diseaseC0684249 18199556-1#160#164#gene1956 18199556-1#117#128#diseaseC0684249 associated_with EGFR,lung cancer
160#164#gene1956117#128#diseaseC1306460 18199556-1#160#164#gene1956 18199556-1#117#128#diseaseC1306460 associated_with EGFR,lung cancer
17#21#gene195669#88#diseaseC0152013 18199556-4#17#21#gene1956 18199556-4#69#88#diseaseC0152013 associated_with EGFR,lung adenocarcinoma
104#108#gene195669#88#diseaseC0152013 18199556-4#104#108#gene1956 18199556-4#69#88#diseaseC0152013 associated_with EGFR,lung adenocarcinoma

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T260 180-212 gene:1956 denotes epidermal growth factor receptor
T261 259-270 disease:C0242379 denotes lung cancer
T262 214-218 gene:1956 denotes EGFR
T263 302-306 gene:1956 denotes EGFR
R1 T260 T261 associated_with epidermal growth factor receptor,lung cancer
R2 T260 T261 associated_with epidermal growth factor receptor,lung cancer
R3 T260 T261 associated_with epidermal growth factor receptor,lung cancer
R4 T262 T261 associated_with EGFR,lung cancer
R5 T262 T261 associated_with EGFR,lung cancer
R6 T262 T261 associated_with EGFR,lung cancer
R7 T263 T261 associated_with EGFR,lung cancer
R8 T263 T261 associated_with EGFR,lung cancer
R9 T263 T261 associated_with EGFR,lung cancer

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 259-263 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T2 749-753 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 259-263 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T2 749-753 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung